Information about Empagliflozin
Empagliflozin (em" pa gli floe' zin) is a specific SGLT-2 inhibitor that in clinical trials was shown to result in a reduction in serum HbA1c levels and better glycemic control in type 2 diabetes, both as monotherapy (in patients who failed to achieve adequate control on diet and exercise) or in combination with insulin, metformin and or sulfonylureas.
FDA approval information for Empagliflozin
Empagliflozin was approved for use in the United States in 2014 and current indications are for management of hyperglycemia in patients with type 2 diabetes in conjunction with diet and exercise and with or without other antidiabetic medications.
Dosage and administration for Empagliflozin
Empagliflozin is available in tablets of 10 and 25 mg under the brand name Jardiance, the recommended initial dose being 10 mg once daily, which can be increased to 25 mg daily. Fixed e combinations of empaglifozin with metformin (Synjardy) and with liraglutide (Glyxambi) are also available.
Side effects of Empagliflozin
Common side effects include symptoms of thirst, urinary tract infections and mycotic genital infections. Less common side effects are hypoglycemia, dehydration, hypovolemia, and serum creatinine elevations.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors
Cost and Coupons - Empagliflozin
- GoodRx compare cost & coupons for Empagliflozin
- Find the lowest cost of Empagliflozin
- Search for Coupons for Empagliflozin
Reviews for Empagliflozin